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Background
The radiolabelled inhibitor of the multidrug efflux trans-
porter P-glycoprotein (P-gp) [
11C]elacridar was devel-
oped as a positron emission tomography (PET) tracer to
assess expression levels of P-gp at the blood-brain bar-
rier (BBB) [1]. [
11C]Elacridar was shown to interact spe-
cifically with P-gp at the rodent BBB, but its brain PET
signal was very low, which was possibly caused by trans-
port of [
11C]elacridar by P-gp [1]. In an attempt to gain
a better understanding of the required properties of an
effective P-gp PET tracer we evaluated
11C-labelled
MC113, a structural analogue of elacridar, which was
characterised as an unambiguous non-transported P-gp
inhibitor and which possesses lower molecular weight,
lower lipophilicity and higher potency for P-gp inhibi-
tion than elacridar (EC50 for inhibition of [
3H]vinblas-
tine transport in Caco-2 cell monolayers: 0.6 µM vs.
2.0 µM for elacridar) [2].
Methods
Female wild-type (n = 3) and Mdr1a/b
−/− (n = 2) mice
(Taconic Inc., USA) underwent paired PET scans with
[
11C]MC113 using a microPET Focus220 scanner
(Siemens, Medical Solutions, USA). A baseline scan
(150 min), during which the P-gp inhibitor tariquidar
(15 mg/kg) was administered i.v. at 60 min after radio-
tracer injection, was followed by a second 60-min scan
at 2 h after administration of tariquidar. Whole-brain
time-activity curves were calculated using the image
analysis software Amide.
Results
[
11C]MC113 was evaluated using an identical set-up
which we had previously used for [
11C]elacridar and
which employed a combination of chemical and genetic
knockout of P-gp [1]. [
11C]MC113 had a 3 times higher
peak brain activity uptake than [
11C]elacridar, but other-
wise behaved identically to [
11C]elacridar, in that brain
activity uptake was higher in Mdr1a/b
−/− than in wild-
type mice and that inhibitor administration increased
brain activity uptake in wild-type mice. However, the
observed effects were smaller for [
11C]MC113 than for
[
11C]elacridar.
Conclusions
Our data suggest that [
11C]MC113 interacts with P-gp at
the murine blood-brain barrier, but as for [
11C]elacridar
its in vivo behaviour points to transport by P-gp. The
higher brain activity uptake of [
11C]MC113 might be an
advantage over [
11C]elacridar for PET imaging of P-gp.
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